Latest Life Sciences News

Page 1 of 3
Vitrafy says it has moved from cryopreservation research into commercial execution, with 19 Guardion devices built, new US partnerships and $38.3 million in cash and term deposits. The next test is converting partner evaluations into recurring revenue after a planned FDA Class II listing in the coming weeks.
Victor Sage
Victor Sage
17 Nov 2026
Microba Life Sciences has been suspended from trading after revised terms for its proposed Genetic Signatures merger left it unable to complete the second tranche of its institutional placement. The company says it is assessing alternative funding while its cashflow runway narrows.
Victor Sage
Victor Sage
17 Nov 2026
EVE Health has signed a binding agreement giving it a 75% share of distributable profit from compounded men’s sexual health products in Australia. The capital-light arrangement preserves EVE’s intellectual property ownership, but provides no minimum volumes or guaranteed revenue.
Victor Sage
Victor Sage
10 Nov 2026
Vitrafy has expanded its US blood and cell therapy partnerships while preparing Guardion for a planned medical device listing by the end of 2026. The company ended September with A$38.3 million in cash and term deposits, but expects spending to rise as validation and manufacturing accelerate.
Victor Sage
Victor Sage
28 Oct 2026
Anatara Lifesciences narrowed its FY2026 loss and ended the year with A$470,917 in cash, but warned that further capital raising is included in its business plan and may be necessary to remain a going concern. Its AOC anti-obesity candidate produced statistically significant results in mice, while mechanism-of-action data remained inconclusive and development was placed on hold.
Victor Sage
Victor Sage
23 Oct 2026
Invion has secured two financing arrangements that could cover up to approximately 85% of its clinical trial costs, providing support for its skin cancer and planned anogenital cancer programs. The funding comes with potential dilution, 16% interest and conditions that leave the actual amount available dependent on drawdowns and R&D tax refunds.
Victor Sage
Victor Sage
21 Oct 2026
Microba has secured a $2.025 million placement while cutting costs further, launching GI Navigator and advancing its proposed merger with Genetic Signatures. The funding comes as the company reports strong Australian testing growth but only about one quarter of cash cover before the raise.
Victor Sage
Victor Sage
20 Oct 2026
Trajan Scientific and Medical (ASX:TRJ) says FY27 has begun with improving revenue, quarterly nEBITDA of about A$3.5 million and a A$1.6 million reduction in net debt. The company expects mid-single-digit organic revenue growth and double-digit nEBITDA growth for the year, although its latest quarterly figures remain unaudited.
Victor Sage
Victor Sage
8 Oct 2026
Vitrafy has added US blood network Versiti to its cryopreservation development programme, with the partnership focused on no-wash platelet preservation and regulatory verification. The deal strengthens the company’s institutional network, but initially generates no revenue and remains subject to US regulatory requirements.
Victor Sage
Victor Sage
30 Sept 2026
Vitrafy Life Sciences reported an 80% revenue surge and halved its net loss, buoyed by US military validation and major blood network partnerships. A $32 million capital raise fuels its US commercial expansion and manufacturing scale-up.
Victor Sage
Victor Sage
4 Aug 2026
Vitrafy Life Sciences has launched a non-underwritten Share Purchase Plan to raise approximately A$2 million, offering existing Australian and New Zealand shareholders the chance to buy shares at A$2.60 each, matching the recent institutional placement price.
Ada Torres
Ada Torres
19 June 2026
Microba Life Sciences secures $5 million in a placement led by Sonic Healthcare to fund its push towards cashflow break-even by 2027, backed by strong diagnostic sales and AI-driven efficiencies.
Ada Torres
Ada Torres
12 June 2026

Browse the archive

Full archive